First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The Company's clinical-stage pipeline includes Rosnilimab, a selective pathogenic T cell depleter, for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator. Rosnilimab is an IgG1 antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. Rosnilimab is designed to selectively deplete pathogenic T cells while sparing non-pathogenic T cells, including naive T cells, to preserve overall immune function and restore immune homeostasis. Its molecules have applicability across a range of autoimmune and inflammatory diseases, including gastroenterology, rheumatology and other areas.
äŒæ¥ã³ãŒã- -
äŒç€Ÿå- -
äžå Žæ¥- -
æé«çµå¶è²¬ä»»è
ãCEOã- -
åŸæ¥å¡æ°- -
蚌åžçš®é¡- -
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°- -
éœåž- -
蚌åžååŒæ- -
åœ- -
éµäŸ¿çªå·- -
é»è©±çªå·- -
ãŠã§ããµã€ã- -
äŒæ¥ã³ãŒã- -
äžå Žæ¥- -
æé«çµå¶è²¬ä»»è
ãCEOã- -